How much does a box of Vorasidenib cost?

Up to now, Voxiranib has not been officially approved for marketing by the National Food and Drug Administration (NMPA) in China. Therefore, there is no medical insurance catalog support in China, and there is no unified retail guide price. At present, domestic medical supplies can only be obtained through international medical channels, such as the Boao Lecheng International Medical Tourism Pilot Project, or through overseas direct mail pharmacies. However, these channels are not subject to government supervision, their prices fluctuate greatly, and there are compliance risks.

In the United States and other countries, Voxanib is available as40 mg Ten thousand RMB, equivalent to approximately 4–5 US dollars (floating according to the exchange rate). Some overseas online pharmacies (such as the "US version" provided by IngPharma VORANIGO) is quoted at about RMB 38 million / boxes. The supply cycle is usually 1–2 weeks, and returns and exchanges are not allowed.

There may be imitations of vorsidenib in countries such as Laos, with relatively low unit prices, but there is little public data. According to MedChemExpress and other international chemical companies, vorsidenib raw materials or small packages (such as 2 mg tablets) The global market reference price is approximately 90–750 US dollars (according to content and packaging specifications). Based on this estimate, the cost of raw materials alone for a box of conventional dosage (40 mg

Since it is currently impossible to obtain state-approved voxanib through formal channels in China, patients must be cautious if they consider using it and must follow compliance paths: such as Boao Lecheng pilot projects and designated medical institutions. In the current market environment, if you purchase it yourself through overseas pharmacies, the price per box is estimated to be between 300,000–40Between RMB 400,000 and RMB 400,000. In addition, as the subsequent phase III clinical trials progress and the drug is applied for listing, if medical insurance can be formally introduced, the price is expected to become more reasonable, and the burden on patients will be significantly reduced.

Currently, Voxanib has not been approved for marketing in China. It mainly relies on overseas channels to enter the market, and the actual cost is relatively high. The market price fluctuates greatly, one box40 mg

Reference materials:https://www.drugs.com/donanemab.html